QQ客服 官方微博 反馈留言

浏览/检索结果: 共9条，第1-9条 帮助 限定条件 发表日期：2019     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 To Take or Not to Take a Side: That Is the Question Reply 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2019, 卷号: 37, 期号: 18 作者:  Qin, Shukui;  Liu, Tianshu;  Li, Jin 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05 CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial 期刊论文 CANCER COMMUNICATIONS, 2019, 卷号: 39 作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Sun, Yan;  Wang, Liwei 收藏  |  浏览/下载：112/0  |  提交时间：2019/12/05 CMAB009  Cetuximab  Irinotecan  Second-line  mCRC  EGFR  KRAS  Immunogenicity  Fluoropyrimidine  Oxaliplatin failure   Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial 期刊论文 ONCOLOGIST, 2019, 卷号: 24, 期号: 8 作者:  Zhou, Ai-Ping;  Bai, Yuxian;  Song, Yan;  Luo, Hong;  Ren, Xiu-Bao 收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05 Anlotinib  Metastatic renal cell cancer  Phase II clinical trial   Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study 期刊论文 LUNG CANCER, 2019, 卷号: 130 作者:  Wu, Yi-Long;  Zhou, Caicun;  Lu, Shun;  Qin, Shukui;  Pan, Hongming 收藏  |  浏览/下载：22/0  |  提交时间：2019/12/05 Asian  Chemotherapy  EGFR  Erlotinib  Non small cell lung cancer   Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial 期刊论文 CANCER COMMUNICATIONS, 2019, 卷号: 39 作者:  Liu, Tianshu;  Qin, Yanru;  Li, Jin;  Xu, Ruihua;  Xu, Jianming 收藏  |  浏览/下载：33/0  |  提交时间：2019/12/05 Gastric cancer  Gastroesophageal junction cancer  HER2  Pertuzumab  Trastuzumab  Chemotherapy  Overall survival  Progression-free survival  Safety  China   Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study 期刊论文 LUNG CANCER, 2019, 卷号: 130, 页码: 18-24 作者:  Wu, Yi-Long;  Zhou, Caicun;  Lu, Shun;  Qin, Shukui;  Pan, Hongming 收藏  |  浏览/下载：28/0  |  提交时间：2019/11/19 Chemotherapy  EGFR  Asian  Non small cell lung cancer  Erlotinib   Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study 期刊论文 Lung Cancer, 2019, 卷号: Vol.130, 页码: 18-24 作者:  Yi-Long Wu;  Caicun Zhou;  Shun Lu;  Shukui Qin;  Hongming Pan 收藏  |  浏览/下载：15/0  |  提交时间：2019/12/17 Asian  Chemotherapy  EGFR  Erlotinib  Non  small  cell  lung  cancer   CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase I 期刊论文 2019, 卷号: 39, 期号: 1, 页码: 28 作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Sun, Yan;  Wang, Liwei 收藏  |  浏览/下载：43/0  |  提交时间：2020/01/03 CMAB009  Cetuximab  Irinotecan  Second-line  mCRC  EGFR  KRAS  Immunogenicity  Fluoropyrimidine  Oxaliplatin failure   Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial 期刊论文 2019, 卷号: 24, 期号: 8, 页码: E702-E708 作者:  Zhou, Ai-Ping;  Bai, Yuxian;  Song, Yan;  Luo, Hong;  Ren, Xiu-Bao 收藏  |  浏览/下载：18/0  |  提交时间：2020/01/03 Anlotinib  Metastatic renal cell cancer  Phase II clinical trial